Hyeon Gyeom Choi

Dr. Hyeon Gyeom Choi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SBSung Hun Bae
Sung Hun Bae
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
SPSo Yeon Park Park
So Yeon Park Park
SCSun-Young Chang
Sun-Young Chang
HKHyoungsu Kim
Hyoungsu Kim
SKSo Hee Kim
So Hee Kim
Tofacitinib, a Janus kinase 1 and 3 inhibitor, is used to treat rheumatoid arthritis. It is mainly metabolized by the cytochromes p450 (CYP) 3A1/2 and CYP2C11 in the liver. Chronic inflammation eventually leads to cirrhosis in patients with rheumatoid arthritis. Isosakuranetin (ISN), a component of Citrus aurantium L., has hepatoprotective effects in rats. This study was performed to determine the effects of ISN on the pharmacokinetics of tofacitinib in rats with N-dimethylnitrosamine-induced liver cirrhosis (LC). After intravenous administration of 10 mg/kg tofacitinib to control (CON), LC, and LC treated with ISN (LC-ISN) rats, the total area under the plasma concentration–time curves (AUC) from time zero to infinity increased by 158% in LC rats compared to those in CON rats; however, the AUC of LC-ISN rats decreased by 35.1% compared to that of LC rat. Similar patterns of AUC changes were observed in the LC and LC-ISN rats after oral administration of 20 mg/kg tofacitinib. These results can be attributed to decreased non-renal clearance (CLNR) and intestinal intrinsic clearance (CLint) in the LC rats and increased intestinal and hepatic CLint in the LC-ISN rats. Our findings imply that ISN treatment in LC rats restored the decrease in either CLNR or CLint, or both, through increased hepatic and intestinal expression of CYP3A1/2 and CYP2C11, which is regulated by the induction of pregnane X receptor (PXR) and constitutive androstane receptor (CAR).

18 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJi-Sang Lee
Ji-Sang Lee
HKHyo-Sung Kim
Hyo-Sung Kim
YJYong Seob Jung
Yong Seob Jung
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
SKSo Hee Kim
So Hee Kim
Fungal infections are prevalent in patients with immune diseases. Voriconazole, a triazole antifungal drug, inhibits the cytochromes CYP3A4 and CYP2C, and tofacitinib, a Janus kinase inhibitor for the treatment of rheumatoid arthritis, is metabolized by CYP3A4 and CYP2C19 in humans. Here, we investigated their interaction during simultaneous administration of both drugs to rats, either intravenously or orally. The area under the plasma concentration–time curve from time zero to time infinity (AUC) of tofacitinib was significantly greater, by 166% and 171%, respectively, and the time-averaged non-renal clearance (CLNR) of tofacitinib was significantly slower (59.5%) than that for tofacitinib alone. An in vitro metabolism study showed non-competitive inhibition of tofacitinib metabolism in the liver and intestine by voriconazole. The concentration/apparent inhibition constant (Ki) ratios of voriconazole were greater than two, indicating that the inhibition of tofacitinib metabolism could be due to the inhibition of the CYP3A1/2 and CYP2C11 enzymes by voriconazole. The pharmacokinetics of voriconazole were not affected by the co-administration of tofacitinib. In conclusion, the significantly greater AUC and slower CLNR of tofacitinib after intravenous and oral administration of both drugs were attributable to the non-competitive inhibition of tofacitinib metabolism via CYP3A1/2 and CYP2C11 by voriconazole in rats.

24 August 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JWJong Mun Won
Jong Mun Won
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
SPSo Yeon Park Park
So Yeon Park Park
JKJang-Hee Kim
Jang-Hee Kim
SKSo Hee Kim
So Hee Kim
Tofacitinib, an inhibitor of Janus kinases (JAKs) 1 and 3, has been shown to be effective in the treatment of rheumatoid arthritis. The incidence of hyperlipidemia has been found to be higher in patients with rheumatoid arthritis. The present study therefore investigated the pharmacokinetics of tofacitinib after its intravenous (10 mg/kg) or oral (20 mg/kg) administration in poloxamer-407-induced hyperlipidemic (PHL) rats. The area under the plasma concentration-time curve from zero to infinity (AUC0–∞) after intravenous administration of tofacitinib was 73.5% higher in PHL than in control rats, owing to slower time-averaged nonrenal clearance (CLNR) in the former. Evaluation of in vitro metabolism showed that the intrinsic clearance (CLint) of tofacitinib was 38.6% lower in PHL than in control rats, owing to the decreased protein expression of hepatic cytochrome P450 (CYP) 3A1/2 and CYP2C11 in PHL rats. Similar results were observed in PHL rats after oral administration of tofacitinib. These results were likely due to the decreased CLNR, CLint, and P-glycoprotein (P-gp) expression in the intestines of PHL compared to control rats. Overall, these findings indicated that hyperlipidemia slowed the metabolism of tofacitinib, increasing its plasma concentrations, and that this reduced metabolism was due to alterations in expression of the proteins CYP3A1/2, CYP2C11, and P-gp in the liver and/or intestines of PHL rats.

15 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SBSung Hun Bae
Sung Hun Bae
SPSo Yeon Park Park
So Yeon Park Park
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
SKSo Hee Kim
So Hee Kim
Background/Objectives: Tofacitinib is a Janus kinase 1 and 3 inhibitor that was developed to treat rheumatoid arthritis. Accordingly, this study aimed to predict plasma tofacitinib concentrations and pharmacokinetic parameters in patients with renal failure through physiologically based pharmacokinetic (PBPK) simulations. Methods: PK-Sim and Simcyp simulators were used, as well as conventional Dedrick plot analysis, employing a single animal extrapolation method. The predictions were compared with previously published data. Results: PBPK simulations of tofacitinib in patients with renal failure closely matched the observed plasma concentration profiles and pharmacokinetic results, including the area under the plasma concentration–time curve (AUC), maximum plasma concentration (Cmax), and time to reach Cmax (Tmax). The ratios of the simulated to observed plasma concentrations and pharmacokinetic parameters for tofacitinib were within a 0.5–2.0-fold error range. Although the results from the Dedrick plot were reasonably good, they were less accurate than those of the PBPK simulations. This was because the Dedrick plot relied solely on preclinical plasma concentration data without incorporating drug physicochemical properties, in vitro data, or physiological and pathophysiological variables. Conclusions: The findings suggest that PBPK simulations using single-species extrapolation effectively provide preliminary estimates of plasma tofacitinib concentration profiles and pharmacokinetic parameters in humans under specific conditions, including renal failure. Furthermore, the results provide a foundation for adjusting tofacitinib dosage and dosing schedules to maintain effective plasma concentrations by considering the pathophysiological characteristics of patients according to their specific diseases.

11 May 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
HCHa-Jin Chun
Ha-Jin Chun
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
EBEUNSOOK BANG
EUNSOOK BANG
JLJang Hoon Lee
Jang Hoon Lee
YKYoung Rong Kim
Young Rong Kim
SKSo Hee Kim
So Hee Kim
Background/Objectives: This study compared the pharmacokinetic (PK)/pharmacodynamic (PD) targets of vancomycin in obese patients using two Bayesian programs to evaluate the accuracy and bias of these estimates. Additionally, population pharmacokinetics in obese patients were compared with those in the general patient population. Methods: Medical records of obese adults [body mass index (BMI) ≥ 30 kg/m2] treated with vancomycin at Ajou University Hospital between 2010 and 2017 were retrospectively reviewed. Patients with peak (Cpeak) and trough (Ctrough) concentrations were included. Vancomycin area under the plasma concentration-time curve (AUC) and Ctrough were estimated using Capcil (ver 6.31) and MwPharm (ver 2.3.1.89) software. Accuracy and bias were analyzed, and population PK parameters were evaluated. Results: A total of 149 cases were analyzed. AUC estimates from one-point sampling using Capcil were significantly lower than the reference values, whereas MwPharm produced estimates closer to the reference with higher accuracy and lower bias. Ctrough estimates from one-point sampling showed high accuracy for both programs. Obese patients exhibit lower volume of distribution, higher total body clearance, and shorter elimination half-life than the general patient population. Conclusions: Vancomycin pharmacokinetics differ in obese patients. Bayesian analysis using MwPharm showed AUC and Ctrough estimates that were closer to the reference values and exhibited lower bias than those obtained with Capcil in this dataset. These findings may support more informed dosing decisions for vancomycin in obese patients.